Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00757250 · ClinicalTrials.gov registry record · Phase 1

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

A Phase 1 study, sponsored by US Biotest.

Terminated
Registry status
Phase 1
Development phase
13
Enrollment target

NCT00757250: Clinical Trial Phase 1 study, sponsored by US Biotest.

NCT00757250 is a Phase 1 study that was terminated before completion, run by US Biotest. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00757250, a Phase 1 study, was terminated before completion, sponsored by US Biotest.

TERMINATED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.

Interventions

  • DRUG Angiotensin 1-7

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2008-09
Est. Completion 2011-12
Phase Phase 1
US Biotest

4 total trials

Why NCT00757250 stopped before completion

NCT00757250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 1 intervention - of which Angiotensin 1-7 is the first listed.

NCT00757250 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00757250 about?

NCT00757250 is a clinical study titled "Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy". The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.

What is the current status of trial NCT00757250?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-09. Estimated completion is 2011-12.

What interventions are being tested in trial NCT00757250?

The interventions under investigation include: Angiotensin 1-7 (DRUG).

Who is sponsoring clinical trial NCT00757250?

This trial is sponsored by US Biotest, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00757250's enrollment target sits among peer trials

13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00757250, the US trial registry maintained by the National Library of Medicine. NCT00757250 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.